Welcome to our dedicated page for Nano-X Imaging Ltd. SEC filings (Ticker: NNOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NANO-X IMAGING LTD filings document foreign private issuer disclosures for a medical imaging technology company with ordinary shares listed under NNOX. Recent Form 6-K reports cover financial results, GAAP and non-GAAP measures, business updates, FDA 510(k) clearance for TAP2D on Nanox.ARC and Nanox.ARC X systems, and commercial developments involving Nanox.ARC deployment.
The filing record also includes capital-structure and governance disclosures, including a registered direct offering of ordinary shares, material agreements, incorporation of exhibits into Form F-3 and Form S-8 registration statements, and annual general meeting proxy materials. These documents describe shareholder voting matters, financing activity, operating results, regulatory updates and corporate reporting controls for the company.
Nano-X Imaging Ltd. is calling a 2026 annual general meeting on September 17, 2026 to vote on four key items: re-election of Class III directors Dan Suesskind and Michael Jackman; an amendment to increase authorized share capital; two equity grants to CEO Erez Meltzer; and re-appointment of Kesselman & Kesselman (PwC Israel) as independent auditors for 2026.
The company seeks to raise its authorized share capital from 100,000,000 to 150,000,000 ordinary shares (par value NIS 0.01) to support financing, strategic transactions, equity compensation and potential Nasdaq compliance actions. Management discloses that cash and cash equivalents and deposits as of March 31, 2026 were not sufficient to support operations for at least one year from August 5, 2026, which it states raises substantial doubt about the company’s ability to continue as a going concern, and expects further equity-linked financing. Shareholders are also asked to approve CEO equity awards of 263,158 and 28,283 RSUs, valued at $600,000 and $28,000 on their respective grant dates, within an equity plan reserve of 6,833,389 shares (about 7.2% of fully diluted share capital).
Nano-X Imaging Ltd scheduled its 2026 annual general meeting of shareholders for September 17, 2026 at 3:00 p.m. Israel time (8:00 a.m. ET) at its Petach Tikva offices. Shareholders of record at the close of business on August 18, 2026 are entitled to notice and to vote.
Shareholders may vote via Internet, by mailing a proxy card, or in person, with proxies to be received by Broadridge by 11:59 p.m. ET on September 16, 2026. The board recommends voting in favor of all proposals. A quorum requires at least two shareholders holding at least 25% of outstanding voting rights, with reduced quorum requirements if the meeting is adjourned.
Nano-X Imaging Ltd. director and Chief Executive Officer Erez Meltzer reported purchasing 9,443 Ordinary Shares on August 10, 2026 at $1.03 per share. The shares were bought indirectly through Oud Nof, a company wholly owned by him, bringing that entity’s holdings to 45,443 Ordinary Shares. He also reports direct ownership of 60,584 Ordinary Shares, and three existing stock option grants over 40,234, 300,000, and 150,000 underlying Ordinary Shares at exercise prices of $2.21, $23.84, and $11.52, expiring in 2030, 2032, and 2034, respectively. The later option grant from April 16, 2024 vests over four years and is scheduled to be fully vested by April 16, 2028.
Nano-X Imaging Ltd completed a registered direct offering to a single long-term institutional investor, issuing 8,000,000 ordinary shares (or pre-funded warrants in lieu of shares) together with 8,000,000 ordinary warrants at a combined purchase price of $1.00 per ordinary share and accompanying warrant (or $0.9999 per pre-funded warrant and accompanying warrant). Gross proceeds were approximately $8.0 million.
The pre-funded warrants have an exercise price of $0.0001 per underlying ordinary share, are immediately exercisable and remain outstanding until exercised, while the ordinary warrants have an exercise price of $1.15 per share, become exercisable six months after issuance and expire five years after closing. Both warrant types are subject to a 4.99% beneficial ownership cap for the investor.
Nano-X engaged A.G.P./Alliance Global Partners as sole placement agent, paying a 5.0% cash fee on gross proceeds and agreeing to reimburse up to $50,000 of expenses. The company accepted 30‑day restrictions on issuing additional equity or most new registration statements, and officers and directors agreed to 30‑day lock-ups on share sales. Net proceeds are intended for working capital and general corporate purposes.
Nano-X Imaging Ltd has priced a registered direct offering to a single institutional investor comprising 3,700,000 ordinary shares, 4,300,000 pre-funded warrants and 8,000,000 ordinary warrants, for $8,000,000 in gross proceeds. Each share unit is priced at $1.00 and each pre-funded unit at $0.9999.
The company expects net proceeds of $7.6 million, excluding any warrant exercises, to be used for working capital and general corporate purposes. Ordinary shares outstanding will rise from 70,588,638 to 78,588,638 assuming full exercise of pre-funded warrants and no exercise of ordinary warrants, representing meaningful dilution.
Management discloses substantial doubt about the company’s ability to continue as a going concern, with an accumulated deficit of $463 million as of March 31, 2026 and dependence on additional financing. An impairment assessment of assets and goodwill is underway and may materially affect final financial results.
Nano-X Imaging Ltd. entered into a securities purchase agreement with a single long-term institutional investor for a registered direct offering of 8,000,000 ordinary shares (or equivalents) and warrants to purchase up to 8,000,000 shares at a combined purchase price of $1.00 per share and accompanying warrant. The warrants have an exercise price of $1.15 per share, become exercisable six months after issuance and expire five years after closing, which is expected on or about August 7, 2026, generating expected gross proceeds of approximately $8 million before fees.
The company plans to use net proceeds for working capital and general corporate purposes. It also reports that, while preparing results for the quarter ended June 30, 2026, it has begun a comprehensive impairment assessment of long-lived assets and goodwill with an external appraiser, and notes that final financial results for the period may differ, potentially materially, from preliminary estimates.
Nano-X Imaging Ltd. has a notice indicating a proposed sale of its ordinary shares on Nasdaq through Oppenheimer & Co. Inc.. The holder plans to sell up to 20,000 ordinary shares, which were issued on 11/22/2024 upon the vesting of RSUs for no cash consideration.
Nano-X Imaging Ltd. filed an initial Form 3 for Chief Financial Officer Guy Nathansohn, providing his first reported status as an officer subject to insider disclosure rules.
The filing reports no transactions or derivative positions and refers to Exhibit 24.1, a Power of Attorney authorizing certain SEC filings.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership in NANO-X IMAGING LTD common stock. BlackRock reported beneficial ownership of 255,435 shares, representing 0.4% of the outstanding common stock as of June 30, 2026.
BlackRock reported sole voting and sole dispositive power over all 255,435 shares, with no shared voting or dispositive power. Various underlying clients or investors may have economic interests in these shares, but no single person is reported to hold more than five percent of the company’s outstanding common shares.
Nano-X Imaging Ltd. director Suesskind Dan S reported open-market purchases of a total of 50,000 Ordinary Shares on July 27, 2026, in two blocks of 25,000 shares at $0.94 and $0.92 per share. The Rule 10b5-1 checkbox was not marked for these transactions.
He also reports outstanding stock options to acquire 12,505 shares at $64.6100, 50,000 shares at $17.6300, and 10,000 shares at $11.5200, with expirations between 2031 and 2033, plus time-vested RSUs granted in 2024 and 2025.